title: Association of Choline Acetyltransferase Gene Polymorphisms (SNPs rs868750G/A, rs1880676G/A, rs2177369G/A and rs3810950G/A) with Alzheimer's Disease Risk: A Meta-Analysis.
abstract: BACKGROUND
  Epidemiological studies have investigated the role of choline acetyltransferase (ChAT) in Alzheimer's disease (AD). ChAT gene polymorphisms (SNPs rs868750G/A, rs1880676G/A, rs2177369G/A, and rs3810950G/A) may be associated with the risk of AD. In this meta-analysis, we determined the relationship between the four polymorphisms and the risk of AD.
  
  
  METHODS
  We searched MEDLINE, EMBASE, and HuGEnet databases for studies linking the four polymorphisms with AD risk. We included 16 articles in our meta-analysis to assess the association between the four polymorphisms and susceptibility to AD by calculating the pooled odds ratios (ORs) and 95% confidence intervals (CIs).
  
  
  RESULTS
  The combined results showed no significant association with rs1880676G/A and rs2177369G/A polymorphisms. The risk of AD (GG+GA versus AA: OR = 0.01, 95%CI = 0.01-0.02, P < 0.05; GG versus GA+AA: OR = 0.85, 95%CI = 0.72-1.00, P = 0.05; GA versus AA: OR = 0.60, 95% CI = 0.37-0.98, P = 0.04) with rs868750G/A polymorphism, or the association of rs3810950G/A polymorphism with AD risk in the overall population (GA versus AA: OR = 0.64, 95% CI = 0.44-0.93, P = 0.02; GG+GA versus AA: OR = 0.62, 95% CI = 0.39-0.97, P = 0.04) or Asian group (GA versus AA: OR = 0.50, 95% CI = 0.32-0.76, P = 0.001, and GG+GA versus AA: OR = 0.46, 95% CI = 0.30-0.09, P = 0.0002) was demonstrated.
  
  
  CONCLUSIONS
  Our meta-analysis suggested that rs1880670G/A, and rs2177369 G/A polymorphisms were not risk factors for AD. However, rs3810950G/A, or rs868750G/A genetic polymorphism was a genetic risk factor for the development of AD. The rs3810950G/A polymorphism had a negative effect on the risk of AD for GA or GG+GA genotypes compared with AA in the overall population or Asians.
authors.affiliation: Department of Rehabilitation medicine, the Second People's Hospital of Hefei City, 230011 Hefei, Anhui Province, China.
authors.forename: Hai
authors.initials: H
authors.lastname: Yuan
authors.affiliation: Department of Rehabilitation medicine, the Second People's Hospital of Hefei City, 230011 Hefei, Anhui Province, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Xia
authors.affiliation: Department of Rehabilitation medicine, the Second People's Hospital of Hefei City, 230011 Hefei, Anhui Province, China.
authors.forename: Kang
authors.initials: K
authors.lastname: Ling
authors.affiliation: Department of Neurology, the Second Affiliated Hospital, Wenzhou Medical University, 325027 Wenzhou, Zhejiang Province, China.
authors.forename: Xiaotong
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Rehabilitation medicine, the Second People's Hospital of Hefei City, 230011 Hefei, Anhui Province, China.
authors.forename: Xiumin
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Neurology, the Second People's Hospital of Hefei City, 230011 Hefei, Anhui Province, China.
authors.forename: Xunping
authors.initials: X
authors.lastname: Du
mesh_terms: D000544:Alzheimer Disease / Q000201:enzymology / Q000235:genetics*; D044466:Asian People; D002795:Choline O-Acetyltransferase / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D016239:MEDLINE; D008297:Male; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
chemical_list: D002795:Choline O-Acetyltransferase